

## PROFESSIONAL CURRICULUM

José Altamirano, MD, MSc



El Dr. Altamirano recibió su formación en Medicina Interna en el Hospital "Dr. Manuel Gea González" y su formación en Ap. Digestivo-Gastroenterología en el Hospital Juárez de la Cd. de México, centrandó su interés en la hepatología y especialmente en la hemorragia digestiva variceal. Posteriormente, realizó el *fellowship* en hepatología en el hospital Vall d' Hebron de Barcelona y perteneció al grupo de complicaciones en la cirrosis y al laboratorio de fibrosis hepática del IDIBAPS en el hospital Clinic de Barcelona durante el periodo de 2009-2015.

En el Hospital Quirónsalud Barcelona, donde ejerce desde el año 2012, realiza consultas externas de **Hepatología-Medicina Interna y Aparato Digestivo**.

*Dr. Altamirano received his training in Internal Medicine at the "Dr. Manuel Gea Gonzalez" Hospital and his training in Gastroenterology at the Juarez Hospital of Mexico City, with special interest in liver diseases and focusing on complications of cirrhosis. He took his clinical fellowship in hepatology at the Vall d'Hebron hospital of Barcelona and belonged to the group of complications of cirrhosis and liver fibrosis laboratory at IDIBAPS-Hospital Clinic of Barcelona during the period of 2009-2015.*

*At Hospital Quirónsalud Barcelona, where he is working since 2012, he takes care of the outpatient clinic of Hepatology-Internal Medicine and Gastroenterology.*

### Professional Education

Master in Research on Liver Diseases (MSc)	Universitat de Barcelona/ Hospital Clinic, Barcelona, Spain	Oct-2009 to Nov-2011
Hepatology Fellowship	Universitat Autonoma de Barcelona/ Hospital Vall d'Hebron, Barcelona, Spain	Mar 2008-Jun 2009
Fellowship	Gastroenterology - Hospital Juarez de México/UNAM México, D.F., México	Mar-2004 to Feb-2007
Residency	Internal Medicine-Hospital "Dr. Manuel Gea Gonzales"/UNAM. México, D.F., México	Mar-2002 to Feb-2004
Social Service	Rural Medicine Practitioner - Mexican Ministry of Health Culiacán, Sinaloa, México	Aug-2001 to Jul-2002
Medical School	Facultad de Medicina-Universidad Autónoma de Guadalajara, Guadalajara, México	Aug-1996 to Jul-2001

### Medical Licensing and Clinical Training

- Certified by the Spanish Council of Medicine (Certificate 0745473/2009/H13504) Sept 2009
- Certification/Homologation of Medical Speciality (Gastroenterology) by Spanish Ministry of Health ( No. Exp 5748-31-2015) in process since August 2015
- Re-Certified by the Mexican Board (Council) of Gastroenterology January 2008
- Certified for ICH Good Clinical Practice Training October 2014
- Certified by Echosens to operate Fibroscan® 502 April 2009

### **Distinctions, Awards and Scholarships**

Scholarship for funding PhD period by the Mexican National Council of Science and Technology (CONACyT, Mexico City, Mexico)	Sept-2015
Scholarship for funding the Fellowship in Clinical Hepatology. Mexican Health Foundation ( Fundhepa-FUNSALUD), México	Mar-2010
Hector Orozco Zepeda Award for a Research Project in Liver Diseases Mexican Health Foundation (Fundhepa - FUNSALUD), México	Feb-2008
Graduated with Honors from the Fellowship Program, Hospital Juarez de México	Feb-2007
Graduated with Honors from MD Program, Universidad Autónoma de Guadalajara, México	Jul-2001

### **Research Funding**

Grant from the Spanish Ministry of Health (98,000€ ) "Effects of Rifaximin in patients with severe alcoholic hepatitis: a pilot study." Hospital Vall d'Hebron, Barcelona, Spain / Collaboration with: Joan Córdoba	Jan-2012
Grant from the Spanish Ministry of Health (125,000€ ) "Alcoholic Liver Disease in Patients with Alcohol Abuse: Identification of Genetic and Environmental Factors and Novel Targets for Therapy " Hospital Clinic, IDIBAPS, Barcelona, Spain. / Collaboration with: Ramón Bataller	Jan-2012
Grant from the Spanish Ministry of Health (128,000€ ) "Endothelial dysfunction and mRNAs in the prognosis of alcoholic hepatitis" Hospital Clinic, IDIBAPS, Barcelona, Spain. / Collaboration with: Juan Caballería	Jan-2013
Grant from the Mexican Council of Science and Technology (CONACyT) (16,340€) "Prognostic Factors and Development of a Histological Classification in Alcoholic Hepatitis " Independent grant support from CONACyT to support clinical research of mexican scientists abroad Collaboration with : Ramon Bataller / Juan Caballeria at the IDIBAPS, Barcelona, Spain.	2015-2016

## Professional Affiliations

American Association for the Study of Liver Diseases	Jan-2014
European Association for Study of the Liver, EASL	Jul-2009
Asociación Mexicana de Gastroenterología	Mar-2009
GETECCU ( Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa)	Mar-2018
Sociedad Española de Patología Digestiva (SEPD)	Jul-2019

## Educational Positions

Invited Professor	Master in Traslational Medicine Universitat de Barcelona/Hospital Clinic, Barcelona, Spain	2011-2012
Invited Professor	Master in Research in Liver Diseases Universitat de Barcelona/Hospital Clinic, Barcelona, Spain	2013-2015
Journal Editor	Journal of Hepatology (Special Section Editor)	2014-2017
Professor	Master Patología Digestiva. Sección Hepatología. Universidad Oberta de Catalunya	2018- to date

## Clinical/Academic Positions

		Dates
Emergency Room Staff	Hospital Quiron Salud Barcelona, Spain	2011-to date
Emergency Room	Hospital CIMA-Sanitas, Barcelona, Spain	2012-2017
Internal Medicine -GI Outpatient Clinic	Hospital Quiron Salud Barcelona, Spain	2015-to date
Clinical Researcher	Vall d'Hebron Research Institute -Internal Medicine Department-Hepatology Unit	2011-to 2017
GI- outpatient clinic-Internal Medicine Department	Clinica Corachan , Barcelona, Spain	2017-to date
Hepatology- outpatient clinic	Gastrodex. Hospital Universitari Quiron Dexeus	2018- to date

## Languages

English (2015-TOEFL iBT Total Score: 87 points)

Spanish (native speaker)

Catalan (speak, understand and read fluently)

### Peer-reviewed Publications:

1. **Altamirano-Gómez JT**, Zapata-Irissón L, González-Angulo A, Ortiz-Salgado AL, Venegas-Sandoval J. Utilidad de MELD, Child-Turcotte-Pugh y Rockall para predecir resangrado y mortalidad en pacientes cirróticos con hemorragia variceal. *Rev Hosp Jua Mex* 2007; 74:126-36.
2. Venegas-Sandoval J, **Altamirano-Gómez JT**, Zapata-Irissón L, González-Angulo A, Rodríguez-Magallán A, Origen C. Alteraciones gasométricas en pacientes cirróticos hospitalizados en la ciudad. de México. *Rev Hosp Jua Mex* 2007; 74:126-36.
3. Rodríguez-Magallán A, Valencia-Romero HS, **Altamirano-Gómez JT**. Etiología y complicaciones de la cirrosis hepática en el Hospital Juárez de México. *Rev Hosp Jua Mex* 2008; 75:257-63.
4. Zapata-Irissón L, Jurado-Nuñez JJ, **Altamirano-Gómez JT**. MELD vs MADDREY: Comparación de 2 Modelos Pronósticos en Hepatitis Alcohólica. *Rev Gastroenterol Mex* 2008; 73:57-62.
5. Augustin S, Muntaner L, **Altamirano JT**, González A, Saperas E, Dot J, Abu-Suboh M, Armengol JR, Malagelada JR, Esteban R, Guardia J, Genescà J. Predicting Early Mortality after Acute Variceal Hemorrhage Based on Classification and Regression Tree Analysis. *Clin Gastroenterol Hepatol* 2009;7: 1347-54.
6. **Altamirano-Gómez J**, Zapata-Irissón L, Augustin-Recio S, Muntaner-Muñoz L, González-Angulo A, Ortiz-Salgado A. Utilidad clínica y predicción de sobrevida intrahospitalaria de 3 escalas pronosticas en hepatitis alcohólica. *Rev Gastroenterol Mex* 2009; 74:18-25.
7. **Altamirano J**, Zapata L, Agustin S, Muntaner L, González-Angulo A, Ortiz AL, Degiau L, Garibay J, Camargo L, Genescà J. Predicting 6-week mortality after acute variceal bleeding: role of Classification and Regression Tree analysis. *Ann Hepatol* 2009; 8:308-15.
8. **Altamirano J**, Zapata L, Poblano M, Rodríguez A, Camargo L, Martínez B, Bataller R. Acute pylephlebitis following gastrointestinal infection: an unrecognized cause of septic shock. *South Med J* 2010; 103:956-9.
9. **Altamirano J**, Bataller R. Cigarette smoking and chronic liver diseases. *Gut* 2010; 59:1159-62.

10. Muntaner L, **Altamirano JT**, Augustin S, González A, Esteban R, Guardia J, Genescà J. High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. *Liver Int* 2010; 30:1123-30.
11. **Altamirano J**, Augustin S, Muntaner L, Zapata L, González-Angulo A, Martínez B, Flores-Arroyo A, Camargo L, Genescà J. Predicting very early rebleeding after acute variceal bleeding based in classification and regression tree analysis (CRTA). *Rev Gastroenterol Mex* 2010; 75:12-2.
12. Bataller R, Rombouts K, **Altamirano J**, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. *Best Practice & Research Clinical Gastroenterology* 2011; 25:231-44.
13. Christophe Van Steenkiste C, Jordi Ribera, Anja Geerts, Montse Pauta, Sònia Tugues, Christophe Casteleyn, Louis Libbrecht, Kim Olievier, Ben Schroyen, Hendrik Reynaert, Leo A van Grunsven, Bram Blomme, Stephanie Coulon, Femke Heindryckx, Martine De Vos, Jean Marie Stassen, Stefan Vinckier, **Jose Altamirano**, Ramón Bataller, Peter Carmeliet, Hans Van Vlierberghe, Isabelle Colle and Manuel Morales-Ruiz. Inhibition of PIGF activity reduces the severity of fibrosis, inflammation and portal hypertension in cirrhotic mice. *Hepatology* 2011; 53:1629-40.
14. **Altamirano J**, Higuera-de laTijera F, Duarte-Rojo A, Martínez-Vázquez MA, Abraldes JG, Herrera-Jiménez LE, Michelena J, Zapata L, Perez-Hernández J, Torre A, Gonzáles-González JA, Cardenas A, Dominguez M, Arroyo V, Ginès P, Caballería J, Bataller R. The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. *Am J Gastroenterol* 2011; 106:1472-80.
15. Zapata L, Flores R, Jurado JJ, Hernández N, **Altamirano J**. Success of medical therapy in a rare case of cecal ameboma. *Rev Gastroenterol Mex* 2011; 76:55-59.
16. Augustin S, **Altamirano J**, González A, Dot J, Abu-Suboh M, Armengol JR, Azpiroz F, Esteban R, Guardia J, Genescà J. Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding. *Am J Gastroenterol* 2011; 106:1787-95.
17. **Altamirano J**, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. *Nat Rev Gastroenterol Hepatol* 2011; 8:491-501.

18. **Altamirano J**, Fagundes C, Dominguez M, García E, Michelena J, Cárdenas A, Guevara M, Pereira G, Torres-Vigil K, Arroyo V, Caballería J, Ginès P, Bataller R. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. *Clin Gastroenterol Hepatol* 2012; 10:65-71.
19. Sancho-Bru P, **Altamirano J**, Rodrigo-Torres D, Coll M, Millán C, Lozano JJ, Miquel R, Arroyo V, Caballería J, Ginès P, Bataller R. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. *Hepatology* 2012; 55:1931-41.
20. **Altamirano J**, Bataller R, Cardenas A, Michelena J, Freixa N, Monrás M, Ríos J, Liccioni A, Caballería J, Gual A, Lligoña A. Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease. *Ann Hepatol* 2012; 11:213-21.
21. Ruiz P, Michelena J, **Altamirano J**, Miquel R, Moreira L, Cárdenas A, Abralde JG, Brugera M, Arroyo V, Ginès P, Caballería J, Bataller R. Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases. *Ann Hepatol*. 2012;11:399-403.
22. . **Altamirano J**, Michelena J, Prado V, Caballería J, Bataller R. Early liver transplantation in alcoholic hepatitis: an option in the treatment of steroid-unresponsive patients. *Gastroenterol Hepatol*. 2012; 35:457-9.
23. Duarte-Rojo A, **Altamirano JT**, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. *Ann Hepatol*. 2012; 11:426-39.
24. Porres-Aguilar M, **Altamirano JT**, Torre-Delgadillo A, Charlton MR, Duarte-Rojo A. Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. *Eur Respir Rev*. 2012; 21:223-233.
25. Michelena J, **Altamirano J**, Caballería J. Protocol for detection of alcohol consumption. *Medicine*. 2012; 11:608-12.
26. . Caballería J, **Altamirano J**, Michelena J, Parés A. Alcohol induced liver disease. *Medicine* 2012; 11:581-589.

27. Affò S, Dominguez M, Lozano JJ, Sancho-Bru P, Rodrigo-Torres D, Morales-Ibanez O, Moreno M, Millán C, Loaeza-Del-Castillo A, **Altamirano J**, García-Pagán JC, Arroyo V, Ginès P, Caballería J, Schwabe RF, Bataller R. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. *Gut* 2013; 62:452-60.
28. Morales-Ibanez O, Domínguez M, Ki SH, Marcos M, Chaves JF, Nguyen-Khac E, Houchi H, Affò S, Sancho-Bru P, **Altamirano J**, Michelena J, García-Pagán JC, Abraldes JG, Arroyo V, Caballería J, Laso FJ, Gao B, Bataller R. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. *Hepatology*. 2013;58(5):1742-56.
29. **Altamirano J**, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, Augustin S, Mookerjee RP, Michelena J, Smyrk TC, Buob D, Leteurtre E, Rincón D, Ruiz P, García-Pagán JC, Guerrero-Marquez C, Jones PD, Barritt AS 4th, Arroyo V, Bruguera M, Bañares R, Ginès P, Caballería J, Roskams T, Nevens F, Jalan R, Mathurin P, Shah VH, Bataller R. A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. *Gastroenterology*. 2014;146(5):1231-1239.
30. Affò S, Morales-Ibanez O, Rodrigo-Torres D, **Altamirano J**, Blaya D, Dapito DH, Millán C, Coll M, Caviglia JM, Arroyo V, Caballería J, Schwabe RF, Ginès P, Bataller R, Sancho-Bru P. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. *Gut*. 2014;63(11):1782-92.
31. Pauta M, Ribera J, Melgar-Lesmes P, Casals G, Rodríguez-Vita J, Reichenbach V, Fernandez-Varo G, Morales-Romero B, Bataller R, Michelena J, **Altamirano J**, Jiménez W, Morales-Ruiz M. Overexpression of angiopoietin-2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. *Liver Int*. 2015;35(4):1383-92.
32. Londoño MC, Abraldes JG, **Altamirano J**, Decaens T, Forns X. Clinical trial watch: reports from the AASLD Liver Meeting®, Boston, November 2014. *J Hepatol*. 2015;62(5):1196-203.
33. Morales-Ibanez O, Affò S, Rodrigo-Torres D, Blaya D, Millán C, Coll M, Perea L, Odena G, Knorpp T, Templin MF, Moreno M, **Altamirano J**, Miquel R, Arroyo V, Ginès P, Caballería J, Sancho-Bru P, Bataller R. Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis. *Gut*. 2016;65:840-51.
34. Michelena J, **Altamirano J**, Abraldes JG, Affò S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, García-Pagán JC, Fernández J, Arroyo V, Ginès P, Louvet A, Mathurin P, Mehal



WZ, Caballería J, Bataller R. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. *Hepatology*. 2015;62(3):762-72

35. Gambato M, Villanueva A, Abraldes JG, **Altamirano J**, Fornis X. Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. *J Hepatol*. 2015;63(3):753-62.

36. Xu MJ, Cai Y, Wang H, **Altamirano J**, Chang B, Bertola A, Odena G, Lu J, Tanaka N, Matsusue K, Matsubara T, Mukhopadhyay P, Kimura S, Pacher P, Gonzalez FJ, Bataller R, Gao B.

Fat-Specific Protein 27/CIDEA Promotes Development of Alcoholic Steatohepatitis in Mice and Humans. *Gastroenterology*. 2015;149(4):1030-41.

37. Affò S, Rodrigo-Torres D, Blaya D, Morales-Ibanez O, Coll M, Millán C, **Altamirano J**, Arroyo V, Caballería J, Bataller R, Ginès P, Sancho-Bru P. Chemokine Receptor Ccr6 Deficiency Alters Hepatic Inflammatory Cell Recruitment and Promotes Liver Inflammation and Fibrosis. *PLoS One*. 2015 Dec 21;10(12):e0145147.

38. Wiegand J, van Bömmel F, Duarte-Rojo A, **Altamirano J**, Abraldes JG, Villanueva A, Berg T. Clinical Trial Watch: Reports from the Liver Meeting, AASLD, San Francisco, November 2015. *J Hepatol*. 2016; 64:1428-45.

39. López-Pelayo H, Miquel L, **Altamirano J**, Blanch JL, Gual A, Lligoña A. Alcohol consumption in upper aerodigestive tract cancer: Role of head and neck surgeons' recommendations. *Alcohol*. 2016;51:51-6.

40. Blaya D, Coll M, Rodrigo-Torres D, Vila-Casadesús M, **Altamirano J**, Llopis M, Graupera I, Perea L, Aguilar-Bravo B, Díaz A, Banales JM, Clària J, Lozano JJ, Bataller R, Caballería J, Ginès P, Sancho-Bru P. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. *Gut*. 2016;65:1535-45.

41. Prado V, Caballería J, Vargas V, Bataller R, **Altamirano J**. Alcoholic hepatitis: How far are we and where are we going? *Ann Hepatol*. 2016 Jul-Aug;15(4):463-73.

42. Bissonnette J, **Altamirano J**, Devue C, Roux O, Payancé A, Lebrec D, Bedossa P, Valla D, Durand F, Ait Oufella H, Sancho-Bru P, Caballeria J, Ginès P, Boulanger CM, Bataller R, Rautou PE. A Prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. *Hepatology*. 2017;66:555-563.
43. Garcia-Saenz-de-Sicilia M, Duvoor C, **Altamirano J**, Chavez-Araujo R, Prado V, de Lourdes Candolo-Martinelli A, Holanda-Almeida P, Becerra-Martins-de-Oliveira B, Fernandez-de-Almeida S, Bataller R, Caballeria J, Duarte-Rojo A. A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis. *Am J Gastroenterol*. 2017;112:306-315.
44. Odena G, Chen J, Lozano JJ, **Altamirano J**, Rodrigo-Torres D, Affo S, Morales-Ibanez O, Matsushita H, Zou J, Dumitru R, Caballeria J, Gines P, Arroyo V, You M, Rautou PE, Valla D, Crews F, Seki E, Sancho-Bru P, Bataller R. LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. *Sci Rep*. 2016; 6:35610. doi: 10.1038/srep35610.
45. Stein E, Cruz-Lemini M, **Altamirano J**, Ndugga N, Couper D, Abraldes JG, Bataller R. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. *J Hepatol*. 2016;65:998-1005.
46. Motola-Kuba M, Escobedo-Arzate A, Tellez-Avila F, **Altamirano J**, Aguilar-Olivos N, González Angulo A, Zamarripa-Dorsey F, Uribe M, Chávez-Tapia NC. Validation of prognostic scores for clinical outcomes in cirrhotic patients with acute variceal bleeding. *Ann Hepatol*. 2016;15:895-901.
47. Perea L, Coll M, Sanjurjo L, Blaya D, El Taghdouini A, Rodrigo-Torres D, **Altamirano J**, Graupera I, Aguilar-Bravo B, Llopis M, Vallverdú J, Caballeria J, van Grunsven LA, Sarrias MR, Ginès P, Sancho-Bru P. Pentraxin-3 Modulates LPS-induced Inflammatory Response and Attenuates Liver Injury. *Hepatology*. 2017;66:953-968.
48. Marin V, Poulsen K, Odena G, McMullen MR, **Altamirano J**, Sancho-Bru P, Tiribelli C, Caballeria J, Rosso N, Bataller R, Nagy LE. Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients. *J Hepatol*. 2017 Jun 22. doi: 10.1016/j.jhep.2017.06.014.
49. **Altamirano J**, López-Pelayo H, Michelena J, Jones PD, Ortega L, Ginès P, Caballería J, Gual A, Bataller R, Lligoña A. Alcohol abstinence in patients surviving an episode of alcoholic

hepatitis: Prediction and impact on long-term survival. *Hepatology*. 2017 Jun 23. doi: 10.1002/hep.29338.

50. Bataller R, Cabezas J, Aller R, Ventura-Cots M, Abad J, Albillos A, **Altamirano J**, Arias-Loste MT, Bañares R, Caballería J, Caballería L, Carrión JA, Diago M, Fernández Rodríguez C, Gallego R, García-Cortes M, García-Monzón C, Genescà J, Ginés P, Hernandez-Guerra M, Jorquera F, Lligoña A, Molina E, Pareja MJ, Planas R, Tomé S, Salmerón J, Romero-Gómez M. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. *Gastroenterol Hepatol*. 2019 Nov 23. pii: S0210-5705(19)30224-9. doi: 10.1016/j.gastrohep.2019.09.006. [Epub ahead of print]

51. Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, Hutmacher F, Lee S, Ventura-Cots M, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, **Altamirano J**, Caballería J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Tu XM, Eckmann L, van der Donk WA, Young R, Lawley TD, Stärkel P, Pride D, Fouts DE, Schnabl B. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. *Nature*. 2019 Nov;575(7783):505-511. doi: 10.1038/s41586-019-1742-x.

52. Argemi J, Latasa MU, Atkinson SR, Blokhin IO, Massey V, Gue JP, Cabezas J, Lozano JJ, Van Booven D, Bell A, Cao S, Verneti LA, Arab JP, Ventura-Cots M, Edmunds LR, Fondevilla C, Stärkel P, Dubuquoy L, Louvet A, Odena G, Gomez JL, Aragon T, **Altamirano J**, Caballería J, Jurczak MJ, Taylor DL, Berasain C, Wahlestedt C, Monga SP, Morgan MY, Sancho-Bru P, Mathurin P, Furuya S, Lackner C, Rusyn I, Shah VH, Thursz MR, Mann J, Avila MA, Bataller R. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. *Nat Commun*. 2019 Jul 16;10(1):3126. doi: 10.1038/s41467-019-11004-3.

53. Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, Abraldes JG, Bosques-Padilla F, Verna EC, Brown RS Jr, Vargas V, **Altamirano J**, Caballería J, Shawcross D, Lucey MR, Louvet A, Mathurin P, Garcia-Tsao G, Ho SB, Tu XM, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. *Hepatology*. 2019 Jun 22. doi: 10.1002/hep.30832.

54. Michelena J, Alonso C, Martínez-Arranz I, **Altamirano J**, Mayo R, Sancho-Bru P, Bataller R, Ginès P, Castro A, Caballería J. Metabolomics Discloses a New Non-invasive Method for the

Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. *Ann Hepatol.* 2019 Jan - Feb;18(1):144-154. doi: 10.5604/01.3001.0012.7906.

55. Arab JP, Roblero JP, **Altamirano J**, Bessone F, Chaves Araujo R, Higuera-De la Tijera F, Restrepo JC, Torre A, Urzua A, Simonetto DA, Abraldes JG, Méndez-Sánchez N, Contreras F, Lucey MR, Shah VH, Cortez-Pinto H, Bataller R. Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). *Ann Hepatol.* 2019 May - Jun;18(3):518-535. doi: 10.1016/j.aohep.2019.04.005.

56. López-Pelayo H, Miquel L, **Altamirano J**, Bataller R, Caballería J, Ortega L, Lligoña A, Gual A. Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: Impact on alcohol relapse. *J Psychosom Res.* 2019 Jan;116:75-82. doi: 10.1016/j.jpsychores.2018.11.020.

#### **Book Chapters:**

1. Michelena J, **Altamirano J**, Bataller R. (2011) Genes and Cirrhosis. In Ginès P, Forns X, Abraldes J.G. Fernández J, Bataller R, Rodès J and Arroyo V. *Therapy in Liver Diseases.* (pp.191-198). Barcelona, Spain: Elsevier Doyma.

2. **Altamirano J**, Moreno M, Caballería J, Bataller R. (2011). Liver Fibrosis: From molecular basis to treatment approaches. *Contreras-Omaya R. Gastroenterología y Hepatología :Temas selectos y visión multidisciplinaria.* (pp.135-154). México City, México: ZarPra

3. **Altamirano J**, Michelena J, Caballería J, Bataller R. (2012). Alcoholic Hepatitis: Diagnosis, prognosis and treatment strategies. Contreras-Omaya R. *Gastroenterología y Hepatología 2 :Temas selectos y visión multidisciplinaria .* (pp.283-294). México City, México: ZarPra

4. **Altamirano J**, Orman ES, Bataller R, Alcoholic Liver Disease. *Yamada's Textbook of Gastroenterology, , 6th Edition* (2015). ISBN: 978-1-118-51206-7.

5. **Altamirano J**, Orman ES, Bataller R, Alcoholic Liver Disease. *Yamada's Atlas of Gastroenterology, , 5th Edition (2016).* ISBN: 978-1-118-49643-5.

#### **Invited Talks**

1. Alcoholic Hepatitis . State of the Art Lecture. Mexican Congress of Hepatology, AMH. Merida, Yucatan , México. 2017.
2. ASH, NASH or Mix Liver Damage. Mexican Congress of Hepatology, AMH. Merida, Yucatan , México. 2017.
3. Non-invasive markers of liver fibrosis. Mexican Congress of Hepatology, AMH. Merida, Yucatan, México. 2017.
4. Metabolismo lipídico, resistencia a la insulina, barrera intestinal, microbioma y efectos sinérgicos. V Edición de actualización en digestología. Hospital Mutua de Terrassa. Terrassa, Bachelona 2017.
5. Obesity, Diabetes and Alcohol Consumption : Sinergistic Effects?. Jornadas de Primavera AEEH. Sevilla 2016.
6. Assessment of Severity and Prognosis in Alcoholic Hepatitis: Scoring Systems and Beyond. 3rd Up Date on Hepatology Bucharest Course. Bucharest, Romania 2016.
7. Prognostic Assessment of Patients with Alcoholic Hepatitis. Hepatology Course. Digestive Endoscopy Workshop 2015, Cluj-Napoca, Romania 2015.
8. Alcoholic Hepatitis. Mexican Internal Medicine Congress. Villahermosa Tabasco, México, , México 2013.
9. Therapeutic Advances in Alcoholic Liver Disease. Digestive Pathology Course. Hospital St Cruz i St. Pau, Barcelona Spain. 2013.
10. The Acutely Ill Patient. Clinical Case Presentation & Interactive Q & A Session. Postgraduate Course. International Liver Congress. European Association for Study of the Liver (EASL). Barcelona, Spain. Apr 2012.
11. Controversies in Alcoholic Liver Disease. Early Morning Workshop. International Liver Congress. European Association for Study of the Liver (EASL). Barcelona, Spain. Apr 2012.
12. Advances in Alcoholic Hepatitis. Postgraduate Course. Mexican Gastroenterology Week. Leon Guanajuato, México, Nov 2011.
13. Current Treatments for Liver Fibrosis. Postgraduate Course. Mexican Gastroenterology Week. Leon Guanajuato, México, Nov 2011.
14. Genetics and Hepatic Encephalopathy. Merck's Symposium. Mexican Gastroenterology Week. Leon Guanajuato, México, Nov 2011.
15. Genetic Prognosis in Alcoholic Liver Disease. 6th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C). Japanese Digestive Disease Week. Fukuoka, Japan. Oct 2011.
16. Acute Variceal Bleeding: Clinical Case Presentation. 1st Annual Meeting of the Mediterranean Association for Study of the Liver. Naples, Italy. Jun 2010.